Watchlist · 72/100Jul 15, 11:35 AM EDT
Roche and Biogen's Kidney Drug Gazyva Gets FDA Priority Review for Expanded Use
RHHBYRHHBF
Roche announced that the FDA has granted priority review for a supplemental Biologics License Application to expand the label of its kidney disease therapy Gazyva/Gazyvaro, developed with Biogen. This expedited review could lead to broader market access and in…
- ▹FDA priority review for label expansion indicates accelerated path and positive regulatory momentum
- ▹Established drug with commercial track record, but expansion into new indication adds uncertainty
Watchlist · 69/100Jul 14, 4:58 PM EDT
Celcuity Secures FDA Nod for Gedatolisib Combo in HR+/HER2- Breast Cancer
CELC
Celcuity (CELC) received FDA approval for Revtorpyk (gedatolisib) combined with fulvestrant, with or without palbociclib, for HR+/HER2- breast cancer after one prior endocrine therapy. The approval, based on the VIKTORIA-1 trial showing significant efficacy, o…
- ▹FDA approval for HR+/HER2- breast cancer with accelerated path and surrogate endpoint
- ▹Single-asset company with no platform or pipeline breadth limits technology score
Neutral · 60/100Jul 16, 8:09 AM EDT
Arbutus and Roivant Launch International Patent Lawsuits Against Pfizer and BioNTech Over COVID Vaccine Technology
PFEBNTXMRNA
Arbutus Biopharma and Roivant Sciences' subsidiary Genevant Sciences filed three international lawsuits against Pfizer and BioNTech, alleging patent infringement related to the COVID-19 vaccine. The suits, filed in Canada, could impact vaccine royalties and ma…
- ▹Patent litigation introduces regulatory uncertainty for Pfizer/BioNTech's COVID vaccine
- ▹Arbutus/Roivant's lipid nanoparticle patents could impact mRNA vaccine technology broadly
Neutral · 57/100Jul 15, 8:12 AM EDT
VivoSim Projects 500%+ Revenue Surge in FY27, Collects $5M Milestone from Eli Lilly
VIVSLLY
VivoSim Labs (VIVS) expects FY27 revenue to grow more than 500%, driven by a $5 million milestone payment from Eli Lilly (LLY) related to a previously sold inflammatory bowel disease drug program. The news highlights the company's potential for significant nea…
- ▹Revenue growth guidance and milestone payment from Eli Lilly indicate commercial validation
- ▹Single-asset micro-cap with no platform or pipeline depth limits technology score
Neutral · 50/100Jul 15, 4:06 PM EDT
Celldex CFO Sam Martin to Step Down in 2027, Search Underway
CLDX
Celldex (CLDX) announced that CFO Sam Martin will retire in 2027 after a decade-long tenure. The company has begun searching for a successor, with Martin staying through March 2027. This leadership change may impact investor sentiment as Celldex advances its p…
- ▹CFO retirement plan is a non-event for pipeline; no impact on regulatory or tech
- ▹Single-asset company with no near-term catalysts; narrative deduct for lack of positive catalysts
High Risk · 47/100Jul 15, 7:59 AM EDT
Senti Biosciences Divests Gene-Circuit Assets to Focus on Regulator Dial Platform
SNTI
Senti Biosciences (SNTI) announced it will spin off its gene-circuit pipeline, including lead candidate SENTI-202, to a private NewCo controlled by Celadon affiliates. Shareholders will receive contingent value rights with up to $60M in milestone payments tied…
- ▹Spin-off reduces pipeline to platform-only, increasing risk; single-asset CVR caps upside.
- ▹Regulator Dial platform is differentiated but unproven; need for financing adds dilution risk.
High Risk · 42/100Jul 15, 10:17 AM EDT
Celcuity Shares Slide Despite FDA Nod for Breast Cancer Drug on Delayed Launch Timeline
CELC
Celcuity (CELC) shares dropped ~15% after the FDA approved its breast cancer therapy Revtorpyk (gedatolisib), but the company announced a launch date of late Q3 2026, later than analysts expected. The delay overshadowed the approval news, raising concerns abou…
- ▹FDA approval is positive but delayed launch to late 2026 raises commercial concerns
- ▹Single-asset micro-cap with limited technology moat and negative market reaction
High Risk · 37/100Jul 16, 9:07 AM EDT
VivoSim Secures $4M Private Placement with Healthcare Investor
VIVS
VivoSim Labs (VIVS) announced a $4.0 million private placement, issuing 4.7 million shares and warrants at $0.85 per unit to a healthcare-focused institutional investor. The capital injection provides near-term funding for operations, though existing sharehold…
- ▹Dilution risk from private placement
- ▹Single-asset micro-cap with no clear catalyst
High Risk · 37/100Jul 15, 8:13 AM EDT
Cardiff Oncology Raises $10M in Direct Stock Offering
CRDF
Cardiff Oncology (CRDF) has entered into agreements to sell 8.57 million shares of common stock and warrants for an additional 8.57 million shares, raising $10 million. The offering provides capital to advance its oncology pipeline, potentially diluting existi…
- ▹Dilutive offering raises capital but signals cash need
- ▹Single-asset micro-cap with no near-term catalysts
High Risk · 37/100Jul 15, 2:22 AM EDT
Q32 Bio Secures $200M in Public Offering to Fund Pipeline
QTTB
Q32 Bio (QTTB) announced the pricing of an underwritten public offering expected to raise approximately $200 million. The company is offering 6.03 million shares at $18.25 each, plus pre-funded warrants for certain investors. This capital infusion supports the…
- ▹Dilutive equity raise of $200M for clinical-stage company
- ▹Single-asset risk with no approved products
High Risk · 10/100Jul 16, 7:43 AM EDT
Quantum Cyber surges on $2M in drone purchase orders tied to facility acquisition
QUCY
Quantum Cyber's subsidiary Quantum Drones received approximately $2.09 million in purchase orders, linked to the acquisition of a 50,000-square-foot manufacturing facility. The orders and facility expansion signal operational growth, potentially boosting inves…
- ▹No biotech relevance; company is in drones/cyber, not pharma.
- ▹Small purchase orders and facility acquisition do not indicate drug development progress.